Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs STRIDES PHARMA SCIENCE - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA STRIDES PHARMA SCIENCE CIPLA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 35.2 22.9 153.8% View Chart
P/BV x 4.1 2.1 190.3% View Chart
Dividend Yield % 0.5 0.2 221.2%  

Financials

 CIPLA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    CIPLA
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
CIPLA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs5861,147 51.0%   
Low Rs357642 55.6%   
Sales per share (Unadj.) Rs207.0317.2 65.3%  
Earnings per share (Unadj.) Rs18.67.8 237.1%  
Cash flow per share (Unadj.) Rs33.225.1 132.4%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.2 379.7%  
Book value per share (Unadj.) Rs195.5274.3 71.3%  
Shares outstanding (eoy) m806.3589.50 900.9%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.8 80.7%   
Avg P/E ratio x25.3114.0 22.2%  
P/CF ratio (eoy) x14.235.7 39.8%  
Price / Book Value ratio x2.43.3 73.9%  
Dividend payout %21.525.5 84.4%   
Avg Mkt Cap Rs m379,91280,058 474.5%   
No. of employees `00025.82.5 1,030.9%   
Total wages/salary Rs m30,2704,341 697.4%   
Avg. sales/employee Rs Th6,459.611,325.8 57.0%   
Avg. wages/employee Rs Th1,171.21,731.4 67.6%   
Avg. net profit/employee Rs Th580.2280.1 207.2%   
INCOME DATA
Net Sales Rs m166,94928,394 588.0%  
Other income Rs m3,442941 365.9%   
Total revenues Rs m170,39129,334 580.9%   
Gross profit Rs m32,0603,965 808.5%  
Depreciation Rs m11,7471,540 762.6%   
Interest Rs m1,9741,962 100.6%   
Profit before tax Rs m21,7821,403 1,552.3%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m6,31297 6,487.2%   
Profit after tax Rs m14,995702 2,135.8%  
Gross profit margin %19.214.0 137.5%  
Effective tax rate %29.06.9 417.9%   
Net profit margin %9.02.5 363.2%  
BALANCE SHEET DATA
Current assets Rs m117,03824,836 471.2%   
Current liabilities Rs m43,93118,993 231.3%   
Net working cap to sales %43.820.6 212.8%  
Current ratio x2.71.3 203.7%  
Inventory Days Days9671 134.9%  
Debtors Days Days85113 75.0%  
Net fixed assets Rs m107,42434,289 313.3%   
Share capital Rs m1,613895 180.2%   
"Free" reserves Rs m156,01823,651 659.7%   
Net worth Rs m157,63024,546 642.2%   
Long term debt Rs m23,69315,513 152.7%   
Total assets Rs m236,62665,437 361.6%  
Interest coverage x12.01.7 701.8%   
Debt to equity ratio x0.20.6 23.8%  
Sales to assets ratio x0.70.4 162.6%   
Return on assets %7.24.1 176.1%  
Return on equity %9.52.9 332.6%  
Return on capital %12.86.9 186.2%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03615,697 357.0%   
Fx outflow Rs m6,764735 919.8%   
Net fx Rs m49,27214,962 329.3%   
CASH FLOW
From Operations Rs m30,6851,871 1,640.3%  
From Investments Rs m1,0405,826 17.9%  
From Financial Activity Rs m-29,488-10,157 290.3%  
Net Cashflow Rs m2,340-2,615 -89.5%  

Share Holding

Indian Promoters % 16.0 27.7 57.8%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 37.8 32.3%  
FIIs % 23.7 8.6 275.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 25.9 101.2%  
Shareholders   161,166 56,241 286.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   ALEMBIC  SUN PHARMA  PIRAMAL ENTERPRISES  FDC  NEULAND LABS  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 31 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 390 points, down 0.8% at 48,644 levels.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 18, 2021 03:36 PM

TRACK CIPLA

CIPLA - AJANTA PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS